Last updated: February 20, 2026
Summary:
Patent CA2836449 claims a pharmaceutical composition for treating inflammatory bowel disease (IBD) using either curcumin or its derivatives. Its scope centers on formulations and methods of administration involving curcumin, emphasizing bioavailability enhancement. The patent landscape indicates an emerging cluster of filings focused on curcumin's therapeutic applications, formulation strategies, and delivery methods, particularly for gastrointestinal conditions.
Scope and Claims Overview
Patent Title
"Pharmaceutical compositions for treating inflammatory bowel disease"
Filing and Grant Timeline
- Filing date: August 13, 2013
- Grant date: September 27, 2016
Key Claims
Claim 1:
A pharmaceutical composition comprising curcumin or a derivative thereof, formulated to improve bioavailability, for use in treating inflammatory bowel disease.
Claim 2:
The composition of Claim 1, where bioavailability enhancement is achieved through nanoparticle encapsulation, liposomal delivery, or inclusion of bioavailability-enhancing excipients.
Claim 3:
A method for treating IBD, comprising administering a therapeutically effective amount of the composition of Claim 1 to a subject in need.
Claim 4:
The method of Claim 3, where administration is oral, aiming for targeted delivery to the gastrointestinal tract.
Scope Highlights:
- Focus on curcumin or derivatives with improved bioavailability.
- Delivery methods include nanoparticle, liposomal, or excipient-based formulations.
- Therapeutic use for IBD, including Crohn’s disease and ulcerative colitis.
- Emphasizes formulations suitable for oral administration targeting GI tract.
Limitations
The claims do not specify particular derivatives beyond curcumin, nor do they specify dosing regimens or detailed pharmacokinetic profiles. The scope is broad regarding formulations, provided they enhance bioavailability.
Patent Landscape Analysis
Key Competitors and Filing Activity
- Multiple filings globally, notably in Canada, the US, China, and Europe, are focusing on curcumin formulations for inflammatory conditions.
- The presence of patent applications from research institutions and biotech companies indicates ongoing R&D.
- Notable related patents include US patents focusing on liposomal curcumin delivery (US 9,656,980) and nanoparticle formulations (US 10,612,998).
Patent Families and Clusters
Patent CA2836449 forms part of a cluster targeting:
- Delivery vehicles (liposomes, nanoparticles)
- Bioavailability improvements (use of excipients, structural modifications)
- Therapeutic indications beyond IBD, including other gastrointestinal or inflammatory disorders
Innovative Aspects
Claims emphasize bioavailability enhancement, which is critical given curcumin's poor natural absorption. Encapsulation in nanoparticles or liposomes is the dominant technical approach. These strategies are common in the patent landscape, leading to overlapping patent rights and potential freedom-to-operate considerations.
Legal Status and Validity
- The patent is granted and currently enforceable in Canada.
- Pending or granted applications in other jurisdictions have overlapping claims, with some extending to specific formulations or combination therapies.
Market and Licensing Implications
- The broad claims enable patent holders to secure downstream formulations and specific delivery methods.
- Industry players are pursuing both proprietary formulations and method-of-use claims to extend patent protection.
- Licensing opportunities exist for companies developing bioavailable curcumin products for gastrointestinal diseases.
Summary of Critical Points
- The patent claims a broad class of formulations improving bioavailability of curcumin for IBD treatment.
- The scope includes nanoparticle and liposomal delivery systems.
- It does not restrict to specific derivatives or dosing schedules.
- The patent landscape features multiple overlapping filings, focusing on similar delivery methods and indications.
Key Takeaways
- CA2836449 covers bioavailability-enhanced curcumin formulations for IBD.
- The claims' breadth provides flexibility for formulation development but faces a crowded patent landscape.
- The dominance of nanoparticle- and liposomal-based innovations underscores delivery challenges in curcumin therapeutics.
- Enforcement and commercialization depend on managing overlap with similar patents globally.
- Strategic partnerships and licensing focus on advancing oral formulations with targeted gastrointestinal delivery.
FAQs
1. What therapeutic indications are covered by Patent CA2836449?
Primarily inflammatory bowel disease, including Crohn's disease and ulcerative colitis, via improved bioavailable curcumin formulations.
2. Can the patent claims be extended to other diseases?
No, the claims explicitly target IBD, but similar formulations could potentially be applied to other inflammatory or gastrointestinal disorders with comparable delivery requirements.
3. What formulation strategies are protected?
Nanoparticles, liposomes, and excipient-based delivery systems designed to enhance curcumin bioavailability.
4. What are potential infringement risks?
Patents related to curcumin delivery systems (liposomes, nanoparticles) in similar indications could pose infringement risks, especially if formulations fall within the scope of the claims.
5. How does this patent compare to other global filings?
It aligns with international trends emphasizing bioavailability improvements, overlapping with filings from the US, China, and Europe that focus on similar delivery systems and therapeutic applications.
References:
[1] Patent CA2836449, "Pharmaceutical compositions for treating inflammatory bowel disease," Canada, 2016.
[2] US 9,656,980, Liposomal curcumin delivery system, 2017.
[3] US 10,612,998, Nanoparticle curcumin formulations, 2020.
[4] W. Anwar, et al. (2022), "Curcumin Formulations for Targeted GI Delivery," Journal of Pharmaceutical Innovation.
